Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/11087
Título
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients
Autor(es)
Carrero, Ana | Berenguer, Juan | Hontañón, Víctor | Guardiola, Josep M | Navarro, Jordi | von Wichmann, Miguel A | Téllez, María Jesús | Quereda, Carmen | Santos, Ignacio | Sanz, José | Galindo, María J | Hernández-Quero, José | Jimenez-Sousa, Maria Angeles ISCIII | Pérez-Latorre, Leire | Bellón, José M | Resino, Salvador ISCIII | Esteban, Herminia | Martínez, Esteban | González-García, Juan
Fecha de publicación
2020-09-15
Cita
Clin Infect Dis. 2021 Oct 5;73(7):e2026-e2033.
Idioma
Inglés
Tipo de documento
research article
Resumen
Little is known about the effects of eradication of HCV on bone mineral density (BMD) and biomarkers of bone remodeling in HIV/HCV coinfected patients.
We prospectively assessed standardized BMD (sBMD) at the lumbar spine and femoral neck, World Health Organization (WHO) BMD categories at both sites, and plasma concentrations of soluble receptor activator of nuclear factor-kappaβ ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV therapy) and at 96 weeks.
A total of 238 patients were included, median age 49.5 years, 76.5% males, 48.3% with cirrhosis, 98.3% on antiretroviral therapy, median CD4+ cell count 527 cells/mm 3, 86.6% with HIV-1 RNA < 50 copies/mL. The prevalence of osteoporosis at baseline at the lumbar spine (LS) and femoral neck (FN) was 17.6% and 7.2%, respectively. Anti-HCV therapy comprised pegylated interferon and ribavirin (PegIFN-RBV) plus one direct-acting antiviral in 53.4%, PegIFN-RBV in 34.5%, and sofosbuvir/RBV in 12.2%. A total of 145 (60.9%) patients achieved sustained viral response (SVR). No significant effect of SVR was observed on sBMD for the interaction between time and SVR either in the LS (P=0.801) or the FN (P=0.911). Likewise, no significant effect of SVR was observed in plasma levels of sRANKL (P=0.205), OPG (P=0.249), and sRANKL/OPG ratio (P=0.123) for the interaction between time and SVR. No significant correlation was found between fibrosis by transient elastography, and LS and FN sBMD, at baseline, and week 96.
SVR was not associated with significant changes in BMD nor biomarkers of bone remodeling in HIV/HCV-coinfected persons.
MESH
Antiviral Agents | Bone Density | Coinfection | HIV | HIV Infections | Hepacivirus | Hepatitis C | Interferon-alpha | Polyethylene Glycols | Recombinant Proteins | Ribavirin | Humans | Male | Middle Aged
Versión en línea
DOI
Aparece en las colecciones